Molecular Signatures of Cutaneous Dupilumab Response
Recruiting · NCT05858619 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, San Francisco
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- 18 years of age or older
- atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7
Exclusion criteria
- Known pregnancy
- Known immunodeficiencies
- Known parasitic infection -
Where it is running
1 location listed across 1 US state.
- University of California, San Francisco - San Francisco, California, United States